Shots:
Insilico Medicine has entered into multiple AI-powered drug discovery collaborations with CMS, focusing on advancing therapeutic programs across CNS & autoimmune disease indications
As per the deal, Insilico will leverage its Pharma.AI platform for target discovery & small-molecule design & optimization, while CMS will lead clinical development, regulatory strategy, trials, & commercialization
Under the…
Shots:
Iambic has partnered with Takeda in a multi-year tech & discovery collaboration to utilize Iambic’s AI drug discovery models toward advancing select high-priority small molecule programs in Takeda’s Oncology, & GI & Inflammation therapeutic areas
The collaboration will leverage Iambic’s AI drug discovery suite & wet lab capabilities, with Takeda also gaining access to…
Shots:
Innovent & Eli Lilly have entered into a strategic collaboration to advance novel medicines in oncology & immunology
As per the deal, Innovent will advance the programs from discovery through P-II PoC trial in China using its antibody platforms, while Lilly will receive exclusive rights to develop & commercialize the assets globally, excl. Greater…
Shots:
Zonsen PepLib Biotech has entered into a worldwide R&D and license agreement with Eli Lilly to jointly advance peptide-based drug candidates using PepLib’s robust & diverse peptide libraries & discovery platforms
As per the deal, PepLib will screen & identify optimal peptide molecules using its in-house platform, while Lilly will oversee IND-enabling activities, clinical…
Shots:
CSPC has entered a strategic collaboration & license deal with AZ to develop long-acting peptides, using CSPC’s sustained-release delivery tech platform & AI-driven peptide drug discovery platform
As per the deal, the Group will collaborate with AZ on novel peptide discovery & long-acting delivery, while AZ will gain exclusive global rights (excl. Greater China)…
Shots:
Pierre Fabre Laboratories has entered into an integrated drug discovery collaboration with Iktos to identify & develop novel small-molecule drug candidates in oncology
As per the deal, Iktos will apply its AI-driven generative design platform to rapidly identify optimized small-molecule candidates for an undisclosed oncology target, while Pierre Fabre will contribute oncology & preclinical expertise…
Shots:
Insilico Medicine has entered into a multi-year R&D collaboration with Servier to identify & develop novel oncology therapeutics for challenging targets using Insilico's Pharma.AI
As per the deal, Servier will share R&D costs &, upon successful identification of potential candidates, assume responsibility for clinical validation, regulatory engagement, & global commercialization of the resulting oncology drug candidates…
Shots:
Dren Bio has partnered with Sanofi to discover & develop next-generation B-cell depleting therapy for the treatment of various autoimmune diseases
As per the deal, Dren Bio will receive $100M upfront & ~$1.7B in milestones, with both parties jointly leading discovery & preclinical work using Dren Bio’s platform, after which Sanofi will handle…
Shots:
Zealand Pharma has entered into a multi-program strategic collaboration & license agreement with OTR to discover & develop oral small molecules for metabolic diseases
OTR & Zealand will jointly discover & develop multiple metabolic disease therapies, with OTR using its discovery platform to lead discovery & preclinical work while Zealand will handle global clinical…
Shots:
CDMOs have become central to the modern biopharmaceutical ecosystem, helping companies accelerate development timelines, navigate rising technical complexity, and bring innovative therapies to market with greater efficiencyÂ
The global CDMO market continues to post strong double-digit growth and is projected to reach nearly $255B by 2025. This momentum is driven by increased outsourcing, the…

